



SEMINAR

# Angiogenesis as Target for Cancer Therapy and Prevention

**Dr. ADRIANA ALBINI**  
**Italian National Institute  
for Research on Cancer, Genova**

**Monday, 6 March 2006, 4.30 pm**

Conference Hall Auditorium  
AREA Science Park  
Padriciano 99  
Trieste

## BIOSKETCH

**Adriana Albin** heads the Laboratory of Molecular Biology and the Translational Oncology Department at the Italian National Institute for Research on Cancer in Genova. She is Deputy Chief of Research at the Institute and is past-President of the Metastasis Research Society (MRS). Dr. Albin has extensive experience in oncology research, developing and utilizing in vitro and in vivo assays for the study of potential inhibitors of tumor invasion and angiogenesis. She has 230 publications in journals with impact factor. In 1987 she established the matrigel invasion assay ("chemoinvasion"), the most widely used assay for testing the invasiveness of malignant cells and screening of antimetastatic drugs. In 1994 she published an in vivo model for Kaposi's sarcoma which has been used for pharmacological studies. She is an expert of the HIV-Tat protein and has recently developed the concept of "angioprevention", the "chemoprevention" in anti-angiogenesis. Today's seminar will deal with the mechanisms of angiogenesis, the therapeutic use of anti-angiogenic agents and the new perspective of angiogenesis as a target of chemoprevention and compounds of natural origin.

**For information: CBM - tel 040 375 7706 – [info@cbm.fvg.it](mailto:info@cbm.fvg.it)**



Interdepartmental Center for Molecular Medicine